A5084091087- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Phagocytosis and Immune Regulation
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Diagnosis and Treatment
- Angiogenesis and VEGF in Cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Head and Neck Surgical Oncology
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Lipids, and Metabolism
- Circadian rhythm and melatonin
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
- Cancer-related gene regulation
- MRI in cancer diagnosis
- Circular RNAs in diseases
- Glioma Diagnosis and Treatment
- Oral health in cancer treatment
- Chronic Lymphocytic Leukemia Research
Guiyang Medical University
2016-2025
Affiliated Hospital of Guizhou Medical University
2016-2025
Guizhou Cancer Hospital
2014-2024
First Hospital of China Medical University
2012-2024
Qingdao University
2021-2024
China Medical University
2011-2024
Affiliated Hospital of Qingdao University
2021-2024
Sun Yat-sen University
2024
First Affiliated Hospital of Liaoning Medical University
2023
Collaborative Drug Discovery (United States)
2019-2021
Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials.
Abstract Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has high incidence Southeast Asia North Africa. To develop these comprehensive guidelines for diagnosis management of NPC, Chinese Society Clinical Oncology (CSCO) arranged multi‐disciplinary team comprising experts from all sub‐specialties NPC to write, discuss, revise guidelines. Based on findings evidence‐based medicine China abroad, domestic have iteratively developed provide proper...
Importance There are currently no therapies approved by the US Food and Drug Administration for nasopharyngeal carcinoma (NPC). Gemcitabine-cisplatin is current standard of care first-line treatment recurrent or metastatic NPC (RM-NPC). Objective To determine whether toripalimab in combination with gemcitabine-cisplatin will significantly improve progression-free survival overall as RM-NPC, compared alone. Design, Setting, Participants JUPITER-02 an international, multicenter, randomized,...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We previously reported significantly improved failure-free survival using gemcitabine plus cisplatin induction...
LBA6000 Background: Patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC) often experience disease relapse even after receiving standard-of-care treatment, e.g. induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT). The benefit of PD-1 inhibitor as adjuvant treatment following IC+CCRT in NPC remains unclear. Methods: (T4N1M0 or T1-4N2-3M0) who have received gemcitabine and cisplatin (GP) IC CCRT were recruited at 11 centers China. They randomly...
332 Background: Evorpacept (Evo) is a high affinity, CD47-blocker with an inactive Fc region designed to safely magnify anticancer antibody dependent cellular phagocytosis. being evaluated across cancers, in combination antibodies and checkpoint inhibitors. Methods: The ASPEN-06 randomized phase 2 trial evaluates Evo standard trastuzumab (T), ramucirumab (R) paclitaxel (P) for the treatment of patients HER2+ GC. Patients nd or 3 rd line advanced metastatic GC that has progressed on after...
The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated cell cycle regulation and the DNA damage response. Its role tumor however, remains unclear. Here, we have shown that COP9 subunit 6 (CSN6) gene amplified human breast cancer specimens, CSN6 upregulated thyroid tumors. expression positively correlated with of murine double minute 2 (MDM2), potent negative regulator p53 suppressor. Expression appeared to...
Chronotherapy is no longer a novel concept in cancer treatment after approximately 20 years of development. Many clinical trials have provided strong supporting evidence that chronomodulated yields better results than traditional dosage regimen. This study aimed to evaluate the adverse reactions, effect on immune functions, and therapeutic efficacy infusion versus flat intermittent cisplatin (DDP) combined with intensity-modulated radiation therapy (IMRT) patients locoregionally advanced...
6001 Background: Patients with locoregionally advanced nasopharyngeal carcinoma (LANPC) have a risk of disease relapse after induction chemotherapy (IC)-concurrent chemoradiotherapy (CCRT). Early phase trials indicated that tislelizumab (PD-1 inhibitor) plus IC followed by CCRT the potential to deepen responses and extend survival in LANPC. Here, we report interim results 3 trial evaluate efficacy safety IC, adjuvant therapy Methods: high-risk LANPC (stage III-IVa, AJCC 8 th Staging System,...
Abstract Background Induction chemotherapy (IC) and concurrent chemoradiotherapy (CCRT) is the standard of care for locoregionally advanced nasopharyngeal carcinoma (LA‐NPC). This intensive treatment regimen increases acute toxicities, which could negatively impact patients' nutritional status. We conducted this prospective, multicentre trial to investigate effects IC CCRT on status in LA‐NPC patients, so as provide evidence further study intervention, was registered ClinicalTrials.gov...
LBA6002 Background: Despite the success of PD-1 blockade plus chemotherapy in recurrent/metastatic NPC, its role LANPC is unproven. This trial evaluated efficacy and safety adding sintilimab (a inhibitor) to IC-CCRT LANPC. Methods: Patients with non-metastatic high-risk (stage III-IVA, excluding T3-4N0/T3N1) were enrolled at 9 centers China, randomized (1:1; stratified by center stage block size four) Standard Arm (gemcitabine cisplatin IC CCRT), or Sintilimab (sintilimab IC-CCRT). 200mg was...
Objective. To evaluate the efficacy and safety of Kangfuxin Solution, a pure Chinese herbal medicine, on mucositis induced by chemoradiotherapy in nasopharyngeal carcinoma patients. Methods. A randomized, parallel-group, multicenter clinical study was performed. total 240 patients were randomized to receive either Solution (test group) or compound borax gargle (control during chemoradiotherapy. Oral mucositis, upper gastrointestinal oral pain evaluated Common Terminology Criteria for Adverse...
LBA2 Background: Gemcitabine-cisplatin (GP) chemotherapy is the standard 1 st line treatment for locally advanced, recurrent or metastatic (r/m) NPC. Toripalimab, a humanized IgG4K monoclonal antibody specific PD-1, provided durable responses in patients (pts) with r/m NPC as monotherapy ≥2 nd setting (POLARIS-02 study). The results of JUPITER-02, randomized, placebo-controlled, double-blinded Phase III trial toripalimab combination GP first-line are summarized. Methods: Pts advanced no...
Patients treated with neoadjuvant chemotherapy (NAC) who achieve a pathologic complete response (pCR) can be identified preoperatively and potentially spared the morbidity of surgery. The objective this retrospective study was to estimate diagnostic accuracy preoperative magnetic resonance imaging (MRI) in predicting pCR patients different molecular subtypes breast cancer provide basis for selection surgical methods.We retrospectively reviewed MRI data from August 2015 December 2018...
Subunit 6 of the COP9 signalosome complex, CSN6, is known to be critical regulation MDM2-p53 axis for cell proliferation and anti-apoptosis, but its many targets remain unclear. Here we show that p57 (Kip2) a target CSN6 negative regulator . associates with , overexpression can decrease steady-state expression ; accordingly, deficiency leads stabilization. Mechanistic studies Skp2, component E3 ligase, which, in turn, facilitates Skp2-mediated protein ubiquitination Loss Skp2 compromised...
Idelalisib, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, is metabolized primarily by aldehyde oxidase to form GS-563117, an inactive metabolite, and lesser extent cytochrome P450 3A uridine 5'-diphospho-glucuronosyltransferase 1A4. In mass balance study, the orally administered idelalisib dose was recovered mainly in feces (∼78%). This study evaluated pharmacokinetics safety of single 150-mg subjects with moderate or severe hepatic impairment age-, sex-, weight-matched, healthy...